Grifols GRFS
NASDAQ GRFS
$8.00 +0.01 (+0.13%)
At close: Aug 21, 2026 · 4:00 PM EDT

Grifols (GRFS) Change in Acquisitions & Divestments (2010 - 2016)

Grifols' (GRFS) quarterly Change in Acquisitions & Divestments came in at $8.7 million in Q4 2016, up 147.47% YoY from $3.5 million in Q1 2016, and up 148.49% on a QoQ basis from -$18.0 million in Q3 2016.

Grifols (GRFS) Change in Acquisitions & Divestments (2010 - 2016) Analysis & Trends

Grifols (GRFS) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $8.7 million in Q4 2016.

  • Quarterly Change in Acquisitions & Divestments rose 147.47% year-over-year to $8.7 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was -$19.8 million (down 15425.5% YoY) and the FY2021 annual result came in at $969.3 million, up 312001.28% from the prior year.
  • Change in Acquisitions & Divestments improved to $8.7 million in Q4 2016, from -$18.0 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $109.0 million in Q2 2012 to a low of -$18.4 million in Q4 2015.
  • A 5-year average of $8.8 million and a median of $2.5 million in 2013 frame the typical range for Change in Acquisitions & Divestments.
  • Annual changes were most pronounced in 2012 — Change in Acquisitions & Divestments jumped 6514.2% — and 2016, when it sank 329.4%.
  • Tracing GRFS's Change in Acquisitions & Divestments over 5 years: stood at -$2.3 million in 2012, then soared by 642.38% to $12.4 million in 2013, then tumbled by 176.09% to -$9.4 million in 2014, then tumbled by 95.28% to -$18.4 million in 2015, then soared by 147.47% to $8.7 million in 2016.
  • The last three Change in Acquisitions & Divestments figures came in at $8.7 million (Q4 2016), -$18.0 million (Q3 2016), and -$18.4 million (Q4 2015), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 652.20 Bn 631.44 Bn 17.26 Bn
2 AbbVie 469.51 Bn 462.94 Bn 12.70 Bn
3 Merck 376.81 Bn 369.67 Bn 12.21 Bn
4 Novartis Ag 303.04 Bn 295.35 Bn 11.24 Bn
5 Astrazeneca 257.61 Bn 252.71 Bn 12.86 Bn
6 Amgen 237.37 Bn 223.38 Bn 7.24 Bn
7 Gilead Sciences 181.73 Bn 178.55 Bn 6.22 Bn
8 Pfizer 159.66 Bn 147.96 Bn 10.94 Bn
9 Gsk 106.24 Bn 102.07 Bn 8.24 Bn
10 Grifols 5.45 Bn 4.45 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2016 8.71 Mn
Dec 31, 2016 8.71 Mn
Sep 30, 2016 -17.97 Mn
Sep 30, 2016 -17.97 Mn
Dec 31, 2015 -18.35 Mn
Dec 31, 2015 -18.35 Mn
Sep 30, 2015 7.83 Mn
Sep 30, 2015 7.83 Mn
Jun 30, 2015 14.68 Mn
Jun 30, 2015 14.68 Mn
Mar 31, 2015 -4.03 Mn
Mar 31, 2015 -4.03 Mn
Dec 31, 2014 -9.40 Mn
Dec 31, 2014 -9.40 Mn
Sep 30, 2014 10.00 Mn
Sep 30, 2014 10.00 Mn
Jun 30, 2014 -2.51 Mn
Jun 30, 2014 -2.51 Mn
Mar 31, 2014 2.51 Mn
Mar 31, 2014 2.51 Mn